LAWRENCEVILLE, N.J. , April 12, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced a presentation and discussion of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in Phase III development for the

DMC Unanimously Recommends Continuation of OPTIMA Study Based on Safety Data From 411 Patients; Enrollment Now at 80% Blinded Progression-Free Survival (PFS) Rate in the OPTIMA Study is Consistent With the Subgroup Patient Population That Showed Benefit in the HEAT Study ThermoDox®-Highlighted

Celsion Enters 2018 with Solid Fundamentals, a Strong Balance Sheet and             an Advancing Clinical Pipeline Company to Hold Conference Call on Tuesday, March 27, 2018 at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , March 27, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology

LAWRENCEVILLE, N.J. , March 20, 2018 (GLOBE NEWSWIRE) --  Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended December 31, 2017 and provide an update on its development programs for ThermoDox®, its

Company to Discuss its Ongoing Pivotal Phase III and its Phase II Clinical Studies in Oncology    LAWRENCEVILLE, N.J. , March 12, 2018 (GLOBE NEWSWIRE) --  -- Celsion Corporation  (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno , Chairman, President and

Discussion Included Overview of Ovarian Cancer Treatment Landscape and Celsion’s Immunotherapy Product Candidate, GEN-1 Presentation Available on Celsion’s Website LAWRENCEVILLE, N.J. , March 05, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) today announced that Premal H.

-Thesis Supporting the Phase III OPTIMA Study Chosen for the Presidential Selection Lecture by the Academic Committee - - Celsion to Host Symposium on Hepatocellular Carcinoma at International Liver Congress 2018 in April -

Company Advances ThermoDox® for Treatment of Primary Liver Cancer Following Independent Data Monitoring Committee's Unanimous Recommendation to Continue Phase III OPTIMA Study OPTIMA Study Enrollment Reached 74% Enrollment at Year-End, With Enrollment Completion Expected in Third Quarter 2018

GEN-1 to Enter the Clinic in Mid-2018 Following a Phase IB Trial Which Demonstrated 100% Disease Control, 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated Compelling Progression-Free Survival Data from Phase IB Trial Supports Development of GEN-1 as a

Collaboration with University of Oxford to Execute a Clinical Trial Using Focused Ultrasound and ThermoDox® for Primary and Metastatic Liver Cancer Presentation of TARDOX Study Phase I Findings at the Upcoming RSNA 2017 Annual Meeting First Ever Study Evaluating ThermoDox® with Focused Ultrasound